‌

US Patent 10392402 Heterocyclic compounds as kinase inhibitors

Patent 10392402 was granted and assigned to Translational Drug Development (Td2) on August, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Translational Drug Development (Td2)

Current Assignee

Translational Drug Development (Td2)

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

August 27, 2019

Patent Application Number

15574800

Date Filed

May 18, 2016

Patent Citations Received

US Patent 11608319 Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and method for performing an in vivo related application that benefits from the inhibition of a kinase

0

US Patent 10633393 Heterocyclic compounds as kinase inhibitors

US Patent 10807966 Heterocyclic compounds as kinase inhibitors

Patent Primary Examiner

Patent abstract

The present invention is directed to certain amides and heterocyclic compounds. The present invention also relates to uses of these compounds to treat several diseases including autoimmune disorders, cardiovascular disorders, inflammation, central nervous system disorders, arterial thrombotic disorders, fibrotic disorders, glaucoma, and neoplastic disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10392402 Heterocyclic compounds as kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.